Objective: To compare the effects of losartan and enalapril on the markers of metabolic syndrome. Methods: One hundred and twenty six newly diagnosed hypertensive patients having other markers of metabolic syndrome participated in this study. The study was performed in the department of pharmacology, college of medicine at Ibn-Sina Teaching Hospital in Mosul city, Iraq, during the period between December 2007 and June 2009. The patients were divided into 2 main groups: 1) Losartan group: consisted of 60 patients, and 2) enalapril group: Consisted of 66 patients. Waist circumference, weight, Body mass index, blood pressure, serum glucose concentration, triglyceride and HDL-cholestrol were measured before and after administration of therapy. The effects of therapy were assessed by statistically comparing the results before and after the drug administration. Results: Comparison of waist circumference, blood pressure, FSG, triglycerides of the patients before drug administration (baseline data), with those of the controls showed a significant elevation, while HDL-cholesterol showed a significant reduction. A significant reduction of waist circumference, BP, FSG and a significant elevation of HDL-cholesterol were also noted after therapy with both losartan and enalapril. Conclusion: Both losartan and enalapril produced a significant reduction of markers of metabolic syndrome and may be regarded as effective drugs for treatment of hypertension in patients with markers of metabolic syndrome.
Introduction
Metabol ic syndrome (MS) is characterized by the variable coexistence of excess body fat, hyperinsulinemia (insulin resistance and glucose intolerance), dyslipidemia (high triglycerides and total cholesterol plasma levels), and hypertension. 1, 2 The presence of metabolic syndrome predicts a two-to-four-fold increase in the risk of cardiovascular disease and death, 3 and the risk of developing type 2 diabetes is increased five-to-nine-fold. 4 Insulin stimulates glucose uptake into tissues, and its ability to do so varies greatly among individuals. Resistance to the action of insulin leads to insulin resistant syndrome. Hyperinsulinemia results to prevent loss of glucose tolerance in insulin resistant individuals. The combination of insulin resistance and compensatory hyperinsulinemia predispose to the development of a cluster of abnormalities, including some degree of glucose intolerance, an increase in plasma triglycerides and a decrease in HDL-cholesterol concentrations. The cluster of changes associated with insulin resistance has been said to comprise syndrome X (metabolic syndrome). 5 The MS pathogenesis is multifactorial and is related to central obesity, a sedentary lifestyle, an unbalanced diet and genetic predisposition. Insulin resistance is described as the central feature of MS. 6 The renin-angiotensin system (RAS) is an important link between MS and cardiovascular diseases. All of the main RAS components are present in adipose tissue. 7 RAS consists primarily of an enzymatic cascade in which angiotensinogen (AGT) is converted to angiotensin I (Ang I), and subsequently to Ang II by the actions of renin and angiotensin converting enzyme (ACE), respectively. 8 Increased levels of Ang II have been observed in both obesity and diabetes patients. RAS components, especially AGT found in adipose tissue are closely related to the Ang II effects on insulin resistance. 9, 10 Furthermore, AGT secretion, as well as Ang II formation in adipocytes are increased in MS patients promoting adipocyte growth, which could explain the positive correlation between high blood pressure and increased adipose-tissue mass in these patients.
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Treatment of the MS encompasses two goals. The first is to address its underlying causes, namely obesity. The second goal is to treat all of its component clinical risk factors. 1, 12 As metabolic syndrome involves a clusters of a number of risk factors including hypertension, dyslipidemia, abdominal obesity, and hyperglycemia; it is therefore in patients with MS, an effective antihypertensive agent with minimal, if any, negative effects on metabolic parameters should be used. 13 The patients in the present study are hypertensive patients having markers of metabolic syndrome. Thus, the aim of the present study is to investigate the effects of two antihypertensive drugs losartan (Ang II receptor blocker) and enalapril (ACE inhibitor) on BP and other markers of MS.
Methods
One hundred and twenty six newly diagnosed hypertensive, patients with other markers of metabolic syndrome participated in this study. They were selected from the out-patient clinic in Ibn-Sina teaching hospital in Mosul city. The study protocol was approved by regional Research Ethics Committees at the College of Medicine and Mosul Health Administration. The study was an open, controlled, comparative, clinical trial of two months duration, performed during the period between 1 st December 2007 and 1 st June 2009. The patients were divided into two main groups: 1) Losartan group: consisted of 60 patients, with an age range between 39 and 68 years. They were kept on losartan (Angizar 50 mg, Micro pharmaceutical industries, Co. Ltd., India) for 2 months on 50 mg once daily oral dose; and 2) enalapril group: consisted of 66 patients, with an age range of 35 to 68 years. They were kept on enalapril (Enalapril 20 mg, Asia pharmaceutical industries, Co. Ltd., Aleppo-Syria), for 2 months on a 20 mg once daily oral dose.
The inclusion criteria included hypertensive patients (stage I) who meet the diagnostic criteria of metabolic syndrome according to the American National Cholesterol Education Program-Adult Treatment Panel III, 2 blood pressure greater than or equal to 130/ 85, waist circumference greater than 102 cm for men and 88 for women, fasting blood glucose levels ≥110 mg/dl (≥6.1 mmol/l), triglycerides ≥150 mg/dl (3.9 mmol/l), and HDL-cholesterol <40 mg/dl (1.04 mmol/l) for men and <50 mg/dl (1.3 mmol/l) for women. Whereas, the exclusion criteria included patients having a current diagnosis of type 1 or type 2 diabetes mellitus, patients on antihypertensive therapy or any drug that affects blood pressure, patients with a history of hepatic, cardiac, renal or blood diseases or other diseases which may interfere with the study, patients having hypersensitivity to angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, patients with a history of severe or resistant hypertension, patients with secondary hypertension of any etiology, pregnant or breast feeding women, and patients with serious disorders which may limit the ability to evaluate the efficacy of the trial drugs.
Seventy apparently healthy, non-obese, normotensive individuals, whose age ranged between 40 and 62 years, were used as a control group. The selection of each control should have the BMI within normal range (18-25 kg/m2).
Waist circumference in (cm) was determined with a standard tape measure, as the point midway between the costal margin and iliac crest in the mid-axillary line, with the subject standing and breathing normally.
14 Blood pressure was measured for each subject by the usual mercury sphygmomanometer from the arm in the sitting position. Measurement was taken after at least five minutes of rest.
Serum glucose concentration (FSG) was estimated by glucoseoxidase-peroxidase colorimetric method, 15 using a kit supplied by BIOCON (Germany). Serum triglycerides and HDL-Cholesterol were measured using special Kits supplied by BIOLABO (France).
The effects of the drugs on the markers of MS were assessed by comparing the results of each drug before and after drug administration.
Statistical analysis was performed using the unpaired t-test to compare between the ages of the two groups, and between the baselines data of the patient and control group. Paired student t-test was used to compare the results before and after drug therapy. The statistical results were considered significant at p=0.05 or less.
Results
The age, weight, BMI and number of males and females of the patients and controls are presented in Table 1 . There were no significant differences between the age of participants in the 3 groups (p>0.5). However, there were significant differences between weight and BMI in the patient groups and the control group, (p<0.001). Comparison of the markers of MS before and after treatment with losartan, or enalapril showed a significant reduction of all markers except for triglycerides, while HDL-cholesterol showed a significant elevation only in the losartan group, (Tables 3, 4) . On the other hand, there was a significant reduction in BMI and weight in patients after therapy administered with either losartan or enalapril. (Table 5 ) 
Discussion
The present study demonstrates a beneficial effect of losartan or enalapril on BP and other markers of MS. A significant reduction of measures of obesity (weight, BMI and WC) were obtained after therapy with losartan or enalapril. Obesity may play a central role in the development of MS, thus increasing obesity is positively correlated with blood pressure, fasting glucose, and triglycerides; and negatively correlated with changes in HDL cholesterol. 16 Reports in the literature demonstrate a relationship between renin angiotensin aldosterone system (RAAS) and obesity; and a significant increase in the activity and concentrations of (RAAS) components have been reported in obese subjects. [17] [18] [19] Engeli et al. 20 reported that weight reduction is associated with a reduction of angiotensinogen levels, renin, aldosterone and ACE activity, as well as the reduction of angiotensinogen levels, which was highly correlated with a decline in waist circumference. In the present study, both enalapril and losartan significantly reduced body weight, BMI, and WC in patients with MS. Enalapril is an ACE inhibitor and losartan is an AII receptor antagonist, they act by reducing the activity of RAAS in the body. Thus, their effects may be related to reducing the activity and the effect of ACE system on obesity.
A significant reduction of BP was obtained after 2 months treatment with both drugs, indicating beneficial effects of these drugs in the treatment of BP in patients with MS. Although both drug classes are highly effective in lowering BP in patients with essential hypertension, [21] [22] [23] their comparative antihypertensive effectiveness are uncertain in patients with metabolic syndrome. 24 The association between BMI and BP have been demonstrated, 25 and there is evidence to suggest that obesity is a casual factor in the development of hypertension in obese individuals. 26 Accordingly, the beneficial effect of losartan and enalapril on BP reported in the present study may be related mostly to their effects on RAAS, and partly on body weight, BMI and WC. The present study demonstrates the beneficial effects of losartan and enalapril on FSG. The patients in the present study were hypertensive; having FSG concentration of ≥110 mg/dl. ACE inhibitors and Ang IIR antagonists may exert beneficial effects on glycemic control through a variety of mechanisms related to the inhibition of the angiotensin II, which activates the sympathetic nervous system resulting in the impairment of insulin secretion and peripheral glucose uptake. Angiotensin II also impairs pancreatic blood flow and enhances insulin resistance. 27 The findings from recent clinical trials support the hypothesis that suppression of RAAS, either by inhibition of ACE or blockade of the AngT1R, substantially lowers the risk of type 2 diabetes. [28] [29] [30] [31] Regarding the effects of losartan and enalapril therapy on triglycerides and HDL-cholesterol; there were no significant effects observed on triglycerides after treatment with losartan or enalapril, and a significant elevation of HDL-Cholesterol was obtained only after therapy with losartan. The effect of losartan on HDL-cholesterol was in agreement with other reports, which also revealed beneficial effects of losartan on HDL-cholesterol levels.
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Conclusion
Losartan and enalapril can reduce the markers of MS and may be regarded as useful antihypertensive agents for the treatment of hypertensive patients having markers of metabolic syndrome.
